(Q33856600)

29 July 2017

1 reference

title

Glucocorticoid-induced osteoporosis. (English)

1 reference

29 July 2017

0 references

Manelli F

1

1 reference

PubMed ID

10707047

29 July 2017

Giustina A

series ordinal

2

1 reference

29 July 2017

1 April 2000

1 reference

Trends in Endocrinology and Metabolism

29 July 2017

1 reference

29 July 2017

11

1 reference

29 July 2017

3

1 reference

29 July 2017

79-85

1 reference

Cytochemical demonstration of the glucocorticoid receptor in skeletal cells of the rat

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Regulation of bone sialoprotein and osteopontin mRNA expression by dexamethasone and 1,25-dihydroxyvitamin D3 in rat bone organ cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Inhibitory actions of glucocorticoids on skeletal growth. Is local insulin-like growth factor I to blame?

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Differential effect of glucocorticoids on calcium absorption and bone mass

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Glucocorticoid osteoporosis--mechanisms and management

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

The role of glucocorticoids in the regulation of Growth Hormone secretion: mechanisms and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Altered pulsatile gonadotropin signaling in nutritional deficiency in the male

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Corticosteroid-induced bone loss in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Quantitative ultrasonometry (QUS) for the evaluation of osteoporosis risk: reference data for various measurement sites, limitations and application possibilities

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus deflazacort.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Active vitamin D metabolites in glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Tamoxifen attenuates the effects of exogenous glucocorticoid on bone formation and growth in piglets.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Corticosteroids and osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Testosterone therapy in glucocorticoid-treated men

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Therapeutic potential of selective modulators of nuclear receptor action

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900234-4

7 January 2021

10.1016/S1043-2760(00)00234-4

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10707047